Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DEA Developing Pain Drug Prescribing Policy

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency is soliciting comments for document intended to “reiterate legal concepts.” New principles will not be outlined, but DEA is hoping to create a “single, comprehensive document” after withdrawing a list of frequently asked questions because of “misstatements.”

You may also be interested in...



Sepracor Lunesta Launch Delayed By Controlled Substance Scheduling

Sepracor plans for Lunesta to be available within the first quarter of 2005 after the completion of formal Drug Enforcement Agency classification of eszopiclone as a Schedule IV substance. The company originally planned to launch the insomnia agent in early January following FDA approval in December.

Elan Prialt Clears FDA, Will Launch In Late January

Intrathecal therapy is indicated for "the management of severe chronic pain in patients…who are intolerant or refractory to other treatment." Elan will promote the non-opioid therapy with 40 to 50 sales reps targeting 3,000 doctors.

Pink Sheet Podcast: US FDA Power Plays, Vaccine EUA Without The Sponsor, RBG’s Impact On Pharma

Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel